Cipla Ltd. — Regulatory Filings 2021

May 20, 2021

20[th] May 2021

(1) BSE Ltd (2) National Stock Exchange of India Ltd Listing Department Listing Department Phiroze Jeejeebhoy Towers, Exchange Plaza, 5[th] floor, Dalal Street, Plot no. C/1, G Block, Mumbai - 400 001 Bandra Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip Code: 500087 Scrip Code: CIPLA EQ

(3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph II, L-1840 Luxembourg

Sub: Press Release - Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RTPCR) test

Dear Sir/Madam,

Please find enclosed press release dated 20[th] May 2021 for the captioned subject.

This is for your information and records.

Kindly acknowledge the receipt.

Thanking you,

Yours faithfully, For Cipla Limited RAJENDR Digitally signed by RAJENDRA A CHOPRA Date: 2021.05.20 CHOPRA 07:57:31 +05'30' Rajendra Chopra Company Secretary

Prepared by: Mandar Kurghode

==> picture [559 x 88] intentionally omitted <==

==> picture [559 x 88] intentionally omitted <==

Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RT-PCR) test

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

Strengthens offerings & continues to be at the forefront of COVID care

Mumbai, India; May 20 2021: Cipla Limited (BSE: 500087; NSE: CIPLA EQ, referred to as “Cipla”) today announced the commercialisation of a polymerase chain reaction (RT-PCR) test kit ‘ViraGen’ for COVID-19 in India, in partnership with Ubio Biotechnology Systems Pvt. Ltd. ViraGen is Cipla’s third offering in the Covid-19 testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.

Cipla is staying true to its promise of providing quality access to healthcare and is at the forefront of COVID Care with the largest portfolio of offerings across the care continuum from protection, detection, treatment and post recovery.

ViraGen is a real-time detection kit approved by the ICMR (Indian Council of Medical Research) and is based on multiplex PCR technology. It helps to identify and detect SARS CoV-2 N Gene and ORF Lab Gene with the sensitivity of 98.6% and the specificity of 98.8% as compared to a standard ICMR test.

This test is designed for the qualitative detection of nucleic acid from SARS-CoV-2 in the upper and lower respiratory specimens from individuals suspected of COVID-19.

ViraGen used for qualitative detection of SARS-CoV-2 will be manufactured by Ubio Biotechnology Systems and marketed and distributed by Cipla through its expansive distribution network across the country.

In the current circumstances, Covid-19 RT PCR testing is extensively used throughout the country as governments, communities, and organizations are working tirelessly to track and curb the spread of the virus. This launch will help address the current testing services and capacity issues while reaffirming the Company’s ongoing expansion in the diagnostic space. The company commence supply of the detection kit from May 25, 2021

Commenting on the partnership, Umang Vohra, MD & Global CEO, Cipla, said , “Cipla has been working relentlessly to ensure accessibility to treatments in this fight against COVID-19. Guided by our core purpose of ‘Caring for Life’, this partnership will enable us to reach out to more people across the country at a crucial time like now”.

About Cipla :

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 80+ markets. Cipla is ranked 3[rd] largest in pharma in India (IQVIA MAT March’ 21), 3[rd] largest in the pharma private market in South Africa (IQVIA MAT March’21),

==> picture [567 x 61] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

==> picture [85 x 10] intentionally omitted <==

and is among the most dispensed generic players in the U.S. For over eight decades, making a difference to patients has inspired every aspect of Cipla’s work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla’s humanitarian approach to healthcare in pursuit of its purpose of ‘Caring for Life’ and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers and all stakeholders. For more, please visit www.cipla.com, or click on Twitter, Facebook, LinkedIn.

For queries, please contact :

Corporate Communications Investor Relations Heena Kanal Naveen Bansal E-Mail: CorpComm@cipla.com E-Mail: Investor.Relations@cipla.com

==> picture [567 x 61] intentionally omitted <==